{"id":"W2948740360","doi":"10.1038/s41591-019-0448-9","title":"Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma","year":2019,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":323,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Merck Sharp and Dohme","keywords":"Dabrafenib; Trametinib; Pembrolizumab; Melanoma; Medicine; Mutant; Cancer research; Oncology; Internal medicine; Vemurafenib; Biology; Immunotherapy; Metastatic melanoma; Genetics; MAPK/ERK pathway; Cancer; Phosphorylation; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008483264,0.0006293497,0.002268863,0.0002968122,0.0002773699,0.0005206048,0.0004340798,0.0007718318,0.004805785],"category_scores_gemma":[0.0009898683,0.0003138249,0.0008639482,0.0003063511,0.0004194739,0.0008855728,0.0002245763,0.00155858,0.000397853],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003910936,"about_ca_system_score_gemma":0.0007733362,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00107831,"about_ca_topic_score_gemma":0.002564909,"domain_scores_codex":[0.9996849,0.0001541951,0.00002113181,0.00003422863,0.00001695395,0.00008863019],"domain_scores_gemma":[0.9996232,0.0001287477,0.00004844799,0.0000223066,0.00001438312,0.0001627895],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9436631,0.004062698,0.0004547462,0.0003710003,0.0003780657,0.0000886518,0.00004580595,0.0003841535,0.01186046,0.0001680375,0.0009705776,0.03755264],"study_design_scores_gemma":[0.4794901,0.4729005,0.02351624,0.0001736461,0.001918504,0.0004409207,0.0002840681,0.001721845,0.01089286,0.0009164371,0.007663972,0.00008084795],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9840342,0.01173211,0.0001243403,0.0007040221,0.0006864867,0.0001287392,0.0004345088,0.00004652407,0.002109103],"genre_scores_gemma":[0.9912642,0.004671343,0.000235663,0.0002271954,0.0002802151,0.0001555547,0.0002759781,0.00000655437,0.002883324],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004805785,"threshold_uncertainty_score":0.01607692,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005862682673053842,"score_gpt":0.2530370359029938,"score_spread":0.24717435322994,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}